GleamWall
中文EN

VRCA Verrica Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1660334 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY370.2%
TTM net income YoY76.6%
TTM EPS YoY88.6%
Revenue 3-yr CAGR57.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-34.2%
Net margin-50.3%
FCF margin—
EBITDA margin-33.9%

Returns

ROE-240.4%
ROA-35.3%
ROIC (approx.)—
Asset turnover0.70x

Leverage & solvency

Liabilities / assets47.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-1.57x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$6.91M$5.86M$5.02M$5.09M$14.34M$12.70M$3.44M$344,000
Cost of revenue——————$700,000$800,000
Gross profit——————$2.74M-$456,000
R&D expense$7.58M$6.03M$3.86M$2.52M$2.21M$1.85M$2.28M$1.17M
SG&A expense$10.36M$10.35M$9.99M$8.12M$9.40M$8.85M$8.85M$9.88M
Operating income-$12.17M-$13.10M-$9.71M-$7.19M$1.63M$1.51M-$8.13M-$11.41M
Interest expense$285,000$164,000$160,000$1.31M$2.09M$2.13M$2.20M$2.35M
Net income-$12.41M-$13.15M-$9.68M-$8.07M-$274,000$204,000-$9.74M-$16.20M
EBITDA-$12.16M-$13.08M-$9.70M-$7.18M$1.65M$1.55M-$8.08M-$11.36M
EPS (basic)-0.58-0.62-0.45—-0.030.02-1.03—
EPS (diluted)-0.58-0.62-0.45—-0.030.02-1.03—
Weighted avg. shares (diluted)21.31M21.31M21.31M—9.49M9.49M9.48M—
Balance sheet
Cash & equivalents$14.39M$11.20M$20.60M$30.15M$21.10M$15.40M$29.59M$46.33M
Receivables$11.24M$10.94M$7.72M$5.26M$7.05M$9.19M$5.61M$48,000
Inventory$2.80M$2.71M$1.97M$2.24M$2.30M$2.52M$2.46M$2.46M
Current assets$36.40M$32.64M$34.13M$42.54M$36.27M$36.78M$39.47M$51.18M
PP&E, net$167,000$177,000$191,000$209,000$225,000$315,000$537,000$589,000
Total assets$39.86M$36.02M$38.79M$47.13M$40.90M$39.11M$42.18M$54.13M
Current liabilities$21.93M$22.44M$16.22M$16.44M$28.91M$29.22M$29.40M$29.01M
Short-term debt———$0$12.46M$12.67M$12.82M$12.94M
Long-term debt———$0$21.62M$24.58M$27.81M$30.98M
Total debt———$0$34.08M$37.25M$40.63M$43.92M
Total liabilities$45.84M$31.71M$22.73M$22.39M$57.94M$56.59M$60.75M$63.99M
Shareholders' equity-$5.97M$4.31M$16.05M$24.74M-$17.04M-$17.48M-$18.58M-$9.86M
Net debt———-$30.15M$12.98M$21.86M$11.04M-$2.41M
Shares outstanding17.18M17.18M17.18M17.18M9.49M9.25M91.79M9.18M
Cash flow statement
Operating cash flow-$9.04M-$9.28M-$9.16M-$4.59M$9.69M-$10.04M-$12.68M-$16.06M
Capital expenditure———$0$0——$0
Free cash flow———-$4.59M$9.69M——-$16.06M
Investing cash flow$0$0$0$0$0$0$0$8,000
Financing cash flow$12.23M-$126,000-$120,000$13.64M-$3.98M-$4.16M-$4.06M$39.43M
Depreciation & amortization$10,000$15,000$17,000$14,000$21,807$45,000$52,000$54,000
Stock-based compensation$1.91M$1.21M$897,000$686,000$718,000$888,000$1.03M$756,000

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.